Ardelyx, Inc. (ARDX)
- Previous Close
3.3800 - Open
3.4200 - Bid 3.8300 x 500
- Ask 3.9300 x 1100
- Day's Range
3.4200 - 4.0400 - 52 Week Range
3.2100 - 8.0600 - Volume
10,684,675 - Avg. Volume
5,313,533 - Market Cap (intraday)
928.309M - Beta (5Y Monthly) 0.76
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2300 - Earnings Date Jul 30, 2025 - Aug 4, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.32
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
www.ardelyx.comRecent News: ARDX
View MorePerformance Overview: ARDX
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ARDX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ARDX
View MoreValuation Measures
Market Cap
928.31M
Enterprise Value
869.47M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.54
Price/Book (mrq)
6.37
Enterprise Value/Revenue
2.40
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-14.86%
Return on Assets (ttm)
-6.58%
Return on Equity (ttm)
-36.26%
Revenue (ttm)
361.71M
Net Income Avi to Common (ttm)
-53.76M
Diluted EPS (ttm)
-0.2300
Balance Sheet and Cash Flow
Total Cash (mrq)
213.95M
Total Debt/Equity (mrq)
124.68%
Levered Free Cash Flow (ttm)
-17.22M